Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
18 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Sponsor: BioNTech SE
Where it's recruiting
Birmingham
Anchorage
Concord · La Jolla
Clermont · Orange City · Stuart · Tampa …
Fort Wayne
Cedar Rapids · Iowa City
Elizabethtown
Frederick
Columbia · Fenton
Hastings
East Brunswick · Florham Park · Paramus
Stony Brook · White Plains
Source: ClinicalTrials.gov · NCT06712316 · last updated 2026-07-01